Democratic attorneys general sue FDA to drop all remaining restrictions on abortion pill

Democratic attorneys general sue FDA to drop all remaining restrictions on abortion pill


Boxes of mifepristone, the first pill given in a medical abortion, are prepared for patients at Women’s Reproductive Clinic of New Mexico in Santa Teresa, U.S., January 13, 2023. 

Evelyn Hockstein | Reuters

A coalition of a dozen Democratic attorneys general sued the Food and Drug Administration on Friday to force the agency to drop all remaining restrictions on the abortion pill, the latest case in an escalating series of legal battles over access to the medication.

The attorneys general asked a federal court in the eastern district of Washington to declare that the abortion pill, mifepristone, is safe and effective and that all remaining restrictions on the medication are unconstitutional.

The lawsuit was led by Washington state Attorney General Bob Ferguson and Oregon’s AG Ellen Rosenblum. The attorneys general of Arizona, Colorado, Connecticut, Delaware, Illinois, Michigan, Nevada, New Mexico, Rhode Island and Vermont were also part of the suit.

The attorneys general also asked the court to prevent the FDA from taking any action that would remove mifepristone from the market or reduce its availability.

Used in combination with misoprostol, mifepristone is the most common method to terminate a pregnancy in the U.S., accounting for about half of all abortions.

The lawsuit filed Friday puts the FDA in the middle of the nation’s deep divisions over access to abortion in the wake of the Supreme Court ruling that overturned Roe v. Wade last summer.

CNBC Health & Science

Read CNBC’s latest global health coverage:

A coalition of physicians who oppose abortion have sued the FDA in federal court in Texas to overturn the agency’s approval of mifepristone, which dates back more than 20 years, and yank the medication from the U.S. market.

The FDA approved mifepristone in 2000, but imposed restrictions on how the medication is dispensed. The agency has gradually eased those restrictions over the years, dropping an in-person dispensing requirement.

But there are still some regulations in place.

In January, the FDA allowed retail pharmacies to dispense mifepristone if they go through a certification process. The patient is required to have a prescription from a health-care provider who is certified under a federal program that monitors mifepristone.

Certified pharmacies can send the pill by mail, but they have to use shipping services that provide tracking information, according to FDA.

CVS and Walgreens have said they are going through the certification process, but they will only dispense mifepristone where it is legal to do so under both state and federal law. At least 12 states have banned abortion, with few exceptions, and other states have tighter restrictions on the medication than what the FDA requires.

Republican attorneys have warned CVS and Walgreens against shipping mifepristone in their states.

Join CNBC’s Healthy Returns on March 29th, where we’ll convene a virtual gathering of CEOs, scientists, investors and innovators in the health care space to reflect on the progress made today to reinvent the future of medicine. Plus, we’ll have an exclusive rundown of the best investment opportunities in biopharma, health-tech and managed care. Learn more and register today: 



Source

Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
Health

Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Medicare drug plans can now cover Eli Lilly‘s blockbuster obesity drug Zepbound for obstructive sleep apnea, CNBC confirmed on Wednesday.  That opens the door for broader access to Zepbound, which is […]

Read More
Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise
Health

Eli Lilly’s lead in the obesity race has grown. Its recent stock performance says otherwise

Eli Lilly investors have received some really good news in recent months with a notable exception of how the stock has performed. Shares of Eli Lilly entered Wednesday’s session off nearly 9% since the Oct. 30 close, the day that the drugmaker’s messy third-quarter earnings report sent the stock down 6%. Zoom out further to […]

Read More
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market 
Health

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market 

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, August 29, 2020. Andrew Kelly | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The U.S. Food and […]

Read More